On March 12, 2025, Pliant Therapeutics adopted a stockholder rights agreement to protect against hostile takeovers, granting one right per share of common stock, exercisable at $12.64 each, with a total of 300,000 shares of preferred stock designated. The rights will become effective for shareholders on March 25, 2025, and expire on March 11, 2026.